Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pract Radiat Oncol. 2019 Mar;9(2):98-101. doi: 10.1016/j.prro.2018.10.015. Epub 2018 Nov 14.
Data on the biology and radiosensitivity of human papillomavirus-related cancers have led many expert radiation oncologists to decrease the radiation dose to target areas in selected situations. At Memorial Sloan Kettering Cancer Center, we have altered our radiation guidelines to allow substantial dose reduction to elective treatment regions and to omit radiation completely in other regions that have historically been included in the elective treatment volume. Here we summarize our current dose prescriptions and briefly explain the rationale behind these choices, which we anticipate will change when additional data mature. These recommendations are based on the American Joint Committee on Cancer seventh edition TNM Staging System and applicable only to patients who receive concurrent platinum-based chemotherapy and in whom both p16 immunohistochemistry and human papillomavirus RNA in situ hybridization tests are positive.
有关人乳头瘤病毒相关性癌症的生物学和放射敏感性的数据，使许多专家放疗肿瘤学家在某些情况下减少了目标区域的放射剂量。在纪念斯隆·凯特琳癌症中心，我们改变了放射指南，允许在选择性治疗区域大幅度减少剂量，并在历史上包含在选择性治疗体积中的其他区域完全免除放射。在这里，我们总结了我们目前的剂量处方，并简要解释了这些选择的基本原理，我们预计随着更多数据的成熟，这些选择将会改变。这些建议基于美国癌症联合委员会第七版 TNM 分期系统，仅适用于接受顺铂为基础的化疗且 p16 免疫组化和人乳头瘤病毒 RNA 原位杂交检测均为阳性的患者。
